Chincarini, A. http://orcid.org/0000-0003-4094-9942
Peira, E.
Corosu, M.
Morbelli, S.
Bauckneht, M.
Capitanio, S.
Pardini, M.
Arnaldi, D.
Vellani, C.
D’Ambrosio, D.
Garibotto, V.
Assal, F.
Paghera, B.
Savelli, G.
Stefanelli, A.
Guerra, U. P.
Nobili, F.
Article History
Received: 30 July 2019
Accepted: 7 January 2020
First Online: 25 January 2020
Compliance with ethical standards
: The scans were acquired in the clinical setting for diagnostic purposes. All subjects (or their legal representative, if demented) were informed that their scans would have been used for research purposes and gave their written consent. All procedures performed were in accordance with the ethical standards of each local institutional Ethics Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The supervising ethics committee for this study is the CER (Comitato Etico della Regione Liguria), based in Genoa, Italy. Ethics Committees approvals included the transfer of imaging data, all anonymized brain amyloid PET were collected from the centers in DICOM format.
: Quality of images was checked by an experienced Nuclear Medicine Physician (S.M.).
: In the past years, Dr. Nobili received fees from Eli-Lilly & Co for giving teaching course on visual reading of [<sup>18</sup>F]Florbetapir, and from Bayer Pharma for participation in an advisory board on [<sup>18</sup>F]Florbetaben.Dr. Pardini receives research support from Novartis and Nutricia and received personal fees from Novartis, Merck, Roche. Dr. Pardini is partly supported by a Curiosity-driven grant from the University of Genoa.All other authors disclose no conflict of interest.